Pre-Made Belatacept Biosimilar, Fusion Protein targeting CD80 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting B7/B7-1/B7.1/BB1/CD28LG/CD28LG1/LAB7 for drug discovery and mechanism of action (MOA) research

Pre-Made Belatacept Biosimilar, Fusion Protein targeting CD80 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting B7/B7-1/B7.1/BB1/CD28LG/CD28LG1/LAB7 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Belatacept, sold under the brand name Nulojix, is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4,[1] which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft and transplant[2] survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. It differs from abatacept (Orencia) by only two amino acids.[medical citation needed]

Belatacept is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Belatacept is a selective T-cell costimulation blocker used in the prophylaxis of organ rejection in adult patients receiving a kidney transplant. Belatacept specifically binds to CD80 and CD86 receptors that are found on the antigen-presenting cell (B cells, macrophages, dendritic cells) to block selective T-cell lymphocyte costimulation. CD80 and CD86 would normally act as the ligands to the CD28 receptor T-cells in which this interaction triggers the activation of T lymphocytes.